In 2022, most states entered into a multi-billion-dollar agreement to settle lawsuits with major manufacturers, distributors, and retailers of opioid drugs. The funding will be disbursed to participating states over the next eighteen years, and many local governments in participating states have started receiving these funds. In this session, speakers will answer frequently asked questions related to revenue recognition requirements and identifying qualifying remediation expenditures.